Naslov Inhibitor plazminogen aktivatora-1 (PAI-1) u bolesnika s upalnim bolestima crijeva Naslov (engleski) Plasminogen activator-1 inhibitor (PAI-1) in patients with
inflammatory bowel diseases Autor Ivan Pekić Mentor Joško Božić (mentor)Član povjerenstva Renata Pecotić (predsjednik povjerenstva)Član povjerenstva Duška Glavaš (član povjerenstva)Član povjerenstva Daniela Šupe-Domić (član povjerenstva)Ustanova koja je dodijelila Sveučilište u Splitu Datum i država obrane 2023-07-14, Hrvatska Znanstveno / umjetničko BIOMEDICINA I ZDRAVSTVO Sažetak Cilj istraživanja: Glavni cilj ovog diplomskog rada bio je istražiti razliku u serumskoj
koncentraciji PAI-1 između bolesnika s upalnim bolestima crijeva u odnosu na kontrolnu
skupinu. Sporedni ciljevi bili su ispitati razliku u serumskoj koncentraciji PAI-1 između
bolesnika s ulceroznim kolitisom i Crohnovom bolesti te istražiti povezanost PAI-1 s
odabranim antropometrijskim, laboratorijskim i kliničkim pokazateljima u bolesnika s upalnim
bolestima crijeva.
Ispitanici i metode: Istraživanje uključuje ukupno 60 ispitanika, i to 30 s upalnom bolesti
crijeva (14 s dijagnozom Crohnove bolesti i 16 ulceroznog kolitisa) te 30 kontrolnih ispitanika.
Svim ispitanicima je uzeta detaljna medicinska anamneza, obavljen klinički pregled te uzet
uzorak venske krvi nakon 10-satnog posta. Serumska koncentracija PAI-1 određena je
korištenjem ProcartaPlex multiplex imunotesta (Thermo Fisher Scientific Inc., Waltham,
SAD).
Rezultati: Pronađena je statički značajno veća koncentracija hemoglobina u kontrolnoj skupini
u odnosu na IBD skupinu (p = 0,005) i značajno veća serumska koncentracija hsCRP u IBD
skupini u odnosu na kontrolnu skupinu (p < 0,001). U bolesnika s upalnim bolestima crijeva
pronađena je veća serumska koncentracija PAI-1 u odnosu na kontrolnu skupinu (8741,5 ±
2153 pg/mL vs. 3687,2 ± 896 pg/mL, p < 0,001). Nije pronađena razlika u serumskim
koncentracijama PAI-1 između bolesnika s Crohnovom bolesti i bolesnika s ulceroznim
kolitisom (8519,0 ± 2396 pg/mL vs. 8997,0 ± 2250 pg/mL, p = 0,729). Nadalje, pronađena je
pozitivna linearna korelacija (r = 0,416, p = 0,022) između razine fekalnog kalprotektina i
serumske koncentracije PAI-1 u bolesnika s upalnim bolestima crijeva.
Zaključci: Serumska koncentracija PAI-1 statistički je značajno veća u skupini bolesnika s
upalnim bolestima crijeva u odnosu na kontrolnu skupinu, ali nije dokazana statistički značajna
razlika u serumskoj koncentraciji PAI-1 između bolesnika s ulceroznim kolitisom i Crohnovom
bolesti. Fekalni kalprotektin ima statistički značajnu povezanost sa serumskom koncentracijom
PAI-1 u upalnim bolestima crijeva.
Sažetak (engleski) Objectives: The main objective of this thesis was to investigate the difference in PAI-1 serum
concentration between patients with inflammatory bowel diseases compared to the control
group. Secondary objectives were to examine the difference in serum PAI-1 concentration
between patients with ulcerative colitis and Crohn's disease and to investigate the association
of PAI-1 with selected anthropometric, laboratory and clinical indicators in patients with
inflammatory bowel diseases.
Subjects and methods: The research included a total of 60 subjects, 30 with inflammatory
bowel disease (14 diagnosed with Crohn's disease and 16 with ulcerative colitis) and 30 control
subjects. A detailed medical history was taken from all subjects, a clinical examination was
performed, and a venous blood sample was taken after a 10-hour fast. Serum PAI-1
concentration was determined using the ProcartaPlex multiplex immunoassay (Thermo Fisher
Scientific Inc., Waltham, USA).
Results: A statically significantly higher concentration of hemoglobin was found in the control
group compared to the IBD group (p = 0.005) and a significantly higher serum concentration
of hsCRP in the IBD group compared to the control group (p < 0.001). In patients with
inflammatory bowel diseases, a higher serum concentration of PAI-1 was found compared to
the control group (8741.5 ± 2153 pg/mL vs. 3687.2 ± 896 pg/mL, p < 0.001). There was no
difference in serum PAI-1 concentrations between patients with Crohn's disease and patients
with ulcerative colitis (8519.0 ± 2396 pg/mL vs. 8997.0 ± 2250 pg/mL, p = 0.729).
Furthermore, a positive linear correlation (r = 0.416, p = 0.022) was found between fecal
calprotectin level and serum PAI-1 concentration in patients with inflammatory bowel diseases.
Conclusions: The serum concentration of PAI-1 was statistically significantly higher in the
group of patients with inflammatory bowel diseases compared to the control group, but there
was no significant difference in the serum concentration of PAI-1 between patients with
ulcerative colitis and Crohn's disease. Fecal calprotectin had a statistically significant
association with serum PAI-1 concentration in inflammatory bowel diseases.
Ključne riječi
Inhibitor plazminogen aktivatora-1
PAI-1
upalne bolesti crijeva
Ključne riječi (engleski)
Plasminogen activator-1 inhibitor
PAI-1
inflammatory bowel diseases
Jezik hrvatski URN:NBN urn:nbn:hr:171:512654 Studijski program Naziv: Medicina Vrsta resursa Tekst Način izrade datoteke Izvorno digitalna Prava pristupa Otvoreni pristup Uvjeti korištenja Datum i vrijeme pohrane 2023-08-01 09:56:51
